Home World News Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer World News Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 342 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New on NCI’s Websites for November 2021 November 5, 2021 Approximately 1 Million of New Maternal Orphans Due to Cancer in... November 28, 2022 Screening People at High Risk for Pancreatic Cancer May Help Them... August 2, 2024 ESMO Targeted Anticancer Therapies Congress 2023 February 24, 2023 Load more HOT NEWS EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma
